| SEQC2 HCC1395 library preparation and DNA input, SNV F1 (Sahraeian et al. 2022 Table S4) | SEQC2 HCC1395/HCC1395BL library-preparation replicates (TruSeq-Nano and Nextera Flex, 1-100 ng DNA) | F1 (SNVs, average over the 6 library pairs as printed), percent | 76.2 | 77.4 | NeuSomatic |
| SEQC2 HCC1395 library preparation and DNA input, SNV F1 (Sahraeian et al. 2022 Table S4) | SEQC2 HCC1395/HCC1395BL library-preparation replicates (TruSeq-Nano and Nextera Flex, 1-100 ng DNA) | F1 (SNVs, tumour LBP_Nextera_T_100ng with normal LBP_Nextera_N_100ng), percent | 89 | 93 | NeuSomatic |
| SEQC2 HCC1395 library preparation and DNA input, SNV F1 (Sahraeian et al. 2022 Table S4) | SEQC2 HCC1395/HCC1395BL library-preparation replicates (TruSeq-Nano and Nextera Flex, 1-100 ng DNA) | F1 (SNVs, tumour LBP_Nextera_T_10ng with normal LBP_Nextera_N_10ng), percent | 90 | 93.1 | NeuSomatic |
| SEQC2 HCC1395 library preparation and DNA input, SNV F1 (Sahraeian et al. 2022 Table S4) | SEQC2 HCC1395/HCC1395BL library-preparation replicates (TruSeq-Nano and Nextera Flex, 1-100 ng DNA) | F1 (SNVs, tumour LBP_Nextera_T_1ng with normal LBP_Nextera_N_1ng), percent | 86.4 | 89.2 | NeuSomatic |
| SEQC2 HCC1395 library preparation and DNA input, SNV F1 (Sahraeian et al. 2022 Table S4) | SEQC2 HCC1395/HCC1395BL library-preparation replicates (TruSeq-Nano and Nextera Flex, 1-100 ng DNA) | F1 (SNVs, tumour LBP_TruSeq_T_100ng with normal LBP_TruSeq_N_100ng), percent | 86.3 | 90.4 | NeuSomatic |
| SEQC2 HCC1395 library preparation and DNA input, SNV F1 (Sahraeian et al. 2022 Table S4) | SEQC2 HCC1395/HCC1395BL library-preparation replicates (TruSeq-Nano and Nextera Flex, 1-100 ng DNA) | F1 (SNVs, tumour LBP_TruSeq_T_10ng with normal LBP_TruSeq_N_10ng), percent | 82.2 | 79.6 | MuSE |
| SEQC2 HCC1395 library preparation and DNA input, SNV F1 (Sahraeian et al. 2022 Table S4) | SEQC2 HCC1395/HCC1395BL library-preparation replicates (TruSeq-Nano and Nextera Flex, 1-100 ng DNA) | F1 (SNVs, tumour LBP_TruSeq_T_1ng with normal LBP_TruSeq_N_1ng), percent | 23.1 | 19.2 | MuSE |
| SEQC2 HCC1395 tumour purity, coverage and normal contamination, SNV F1 (Sahraeian et al. 2022 Table S3) | SEQC2 tumour-normal titration: HCC1395 gDNA mixed with HCC1395BL gDNA at 5-100% tumour purity, 10x-300x WGS | F1 (SNVs, average over the 47 purity-coverage pairs as printed), percent | 51.7 | 66.1 | NeuSomatic |
| SEQC2 HCC1395 tumour purity, coverage and normal contamination, SNV F1 (Sahraeian et al. 2022 Table S3) | SEQC2 tumour-normal titration: HCC1395 gDNA mixed with HCC1395BL gDNA at 5-100% tumour purity, 10x-300x WGS | F1 (SNVs, tumour SPP_100x_10%T with normal SPP_100x_100%N), percent | 25 | 63 | NeuSomatic |
| SEQC2 HCC1395 tumour purity, coverage and normal contamination, SNV F1 (Sahraeian et al. 2022 Table S3) | SEQC2 tumour-normal titration: HCC1395 gDNA mixed with HCC1395BL gDNA at 5-100% tumour purity, 10x-300x WGS | F1 (SNVs, tumour SPP_100x_100%T with normal SPP_100x_100%N), percent | 92.6 | 95.9 | NeuSomatic |
| SEQC2 HCC1395 tumour purity, coverage and normal contamination, SNV F1 (Sahraeian et al. 2022 Table S3) | SEQC2 tumour-normal titration: HCC1395 gDNA mixed with HCC1395BL gDNA at 5-100% tumour purity, 10x-300x WGS | F1 (SNVs, tumour SPP_100x_20%T with normal SPP_100x_100%N), percent | 59.4 | 82.6 | NeuSomatic |
| SEQC2 HCC1395 tumour purity, coverage and normal contamination, SNV F1 (Sahraeian et al. 2022 Table S3) | SEQC2 tumour-normal titration: HCC1395 gDNA mixed with HCC1395BL gDNA at 5-100% tumour purity, 10x-300x WGS | F1 (SNVs, tumour SPP_100x_5%T with normal SPP_100x_100%N), percent | 3.7 | 33.6 | NeuSomatic |
| SEQC2 HCC1395 tumour purity, coverage and normal contamination, SNV F1 (Sahraeian et al. 2022 Table S3) | SEQC2 tumour-normal titration: HCC1395 gDNA mixed with HCC1395BL gDNA at 5-100% tumour purity, 10x-300x WGS | F1 (SNVs, tumour SPP_100x_50%T with normal SPP_100x_100%N), percent | 85.5 | 92.8 | NeuSomatic |
| SEQC2 HCC1395 tumour purity, coverage and normal contamination, SNV F1 (Sahraeian et al. 2022 Table S3) | SEQC2 tumour-normal titration: HCC1395 gDNA mixed with HCC1395BL gDNA at 5-100% tumour purity, 10x-300x WGS | F1 (SNVs, tumour SPP_100x_75%T with normal SPP_100x_100%N), percent | 90.1 | 95.2 | NeuSomatic |
| SEQC2 HCC1395 tumour purity, coverage and normal contamination, SNV F1 (Sahraeian et al. 2022 Table S3) | SEQC2 tumour-normal titration: HCC1395 gDNA mixed with HCC1395BL gDNA at 5-100% tumour purity, 10x-300x WGS | F1 (SNVs, tumour SPP_10x_10%T with normal SPP_10x_100%N), percent | 3.8 | 4.7 | NeuSomatic |
| SEQC2 HCC1395 tumour purity, coverage and normal contamination, SNV F1 (Sahraeian et al. 2022 Table S3) | SEQC2 tumour-normal titration: HCC1395 gDNA mixed with HCC1395BL gDNA at 5-100% tumour purity, 10x-300x WGS | F1 (SNVs, tumour SPP_10x_100%T with normal SPP_10x_100%N), percent | 49.6 | 33.9 | MuSE |
| SEQC2 HCC1395 tumour purity, coverage and normal contamination, SNV F1 (Sahraeian et al. 2022 Table S3) | SEQC2 tumour-normal titration: HCC1395 gDNA mixed with HCC1395BL gDNA at 5-100% tumour purity, 10x-300x WGS | F1 (SNVs, tumour SPP_10x_20%T with normal SPP_10x_100%N), percent | 12.3 | 12.2 | Tie |
| SEQC2 HCC1395 tumour purity, coverage and normal contamination, SNV F1 (Sahraeian et al. 2022 Table S3) | SEQC2 tumour-normal titration: HCC1395 gDNA mixed with HCC1395BL gDNA at 5-100% tumour purity, 10x-300x WGS | F1 (SNVs, tumour SPP_10x_5%T with normal SPP_10x_100%N), percent | 1.1 | 1.7 | NeuSomatic |
| SEQC2 HCC1395 tumour purity, coverage and normal contamination, SNV F1 (Sahraeian et al. 2022 Table S3) | SEQC2 tumour-normal titration: HCC1395 gDNA mixed with HCC1395BL gDNA at 5-100% tumour purity, 10x-300x WGS | F1 (SNVs, tumour SPP_10x_50%T with normal SPP_10x_100%N), percent | 36.9 | 29 | MuSE |
| SEQC2 HCC1395 tumour purity, coverage and normal contamination, SNV F1 (Sahraeian et al. 2022 Table S3) | SEQC2 tumour-normal titration: HCC1395 gDNA mixed with HCC1395BL gDNA at 5-100% tumour purity, 10x-300x WGS | F1 (SNVs, tumour SPP_10x_75%T with normal SPP_10x_100%N), percent | 47 | 33.8 | MuSE |
| SEQC2 HCC1395 tumour purity, coverage and normal contamination, SNV F1 (Sahraeian et al. 2022 Table S3) | SEQC2 tumour-normal titration: HCC1395 gDNA mixed with HCC1395BL gDNA at 5-100% tumour purity, 10x-300x WGS | F1 (SNVs, tumour SPP_200x_10%T with normal SPP_200x_100%N), percent | 40.4 | 75.9 | NeuSomatic |
| SEQC2 HCC1395 tumour purity, coverage and normal contamination, SNV F1 (Sahraeian et al. 2022 Table S3) | SEQC2 tumour-normal titration: HCC1395 gDNA mixed with HCC1395BL gDNA at 5-100% tumour purity, 10x-300x WGS | F1 (SNVs, tumour SPP_200x_100%T with normal SPP_200x_100%N), percent | 95 | 97 | NeuSomatic |
| SEQC2 HCC1395 tumour purity, coverage and normal contamination, SNV F1 (Sahraeian et al. 2022 Table S3) | SEQC2 tumour-normal titration: HCC1395 gDNA mixed with HCC1395BL gDNA at 5-100% tumour purity, 10x-300x WGS | F1 (SNVs, tumour SPP_200x_20%T with normal SPP_200x_100%N), percent | 72 | 88.4 | NeuSomatic |
| SEQC2 HCC1395 tumour purity, coverage and normal contamination, SNV F1 (Sahraeian et al. 2022 Table S3) | SEQC2 tumour-normal titration: HCC1395 gDNA mixed with HCC1395BL gDNA at 5-100% tumour purity, 10x-300x WGS | F1 (SNVs, tumour SPP_200x_5%T with normal SPP_200x_100%N), percent | 8.3 | 50.7 | NeuSomatic |
| SEQC2 HCC1395 tumour purity, coverage and normal contamination, SNV F1 (Sahraeian et al. 2022 Table S3) | SEQC2 tumour-normal titration: HCC1395 gDNA mixed with HCC1395BL gDNA at 5-100% tumour purity, 10x-300x WGS | F1 (SNVs, tumour SPP_200x_50%T with normal SPP_200x_100%N), percent | 88.7 | 95.7 | NeuSomatic |
| SEQC2 HCC1395 tumour purity, coverage and normal contamination, SNV F1 (Sahraeian et al. 2022 Table S3) | SEQC2 tumour-normal titration: HCC1395 gDNA mixed with HCC1395BL gDNA at 5-100% tumour purity, 10x-300x WGS | F1 (SNVs, tumour SPP_200x_75%T with normal SPP_200x_100%N), percent | 92.5 | 97 | NeuSomatic |
| SEQC2 HCC1395 tumour purity, coverage and normal contamination, SNV F1 (Sahraeian et al. 2022 Table S3) | SEQC2 tumour-normal titration: HCC1395 gDNA mixed with HCC1395BL gDNA at 5-100% tumour purity, 10x-300x WGS | F1 (SNVs, tumour SPP_300x_10%T with normal SPP_300x_100%N), percent | 46.9 | 81.2 | NeuSomatic |
| SEQC2 HCC1395 tumour purity, coverage and normal contamination, SNV F1 (Sahraeian et al. 2022 Table S3) | SEQC2 tumour-normal titration: HCC1395 gDNA mixed with HCC1395BL gDNA at 5-100% tumour purity, 10x-300x WGS | F1 (SNVs, tumour SPP_300x_100%T with normal SPP_300x_100%N), percent | 96.7 | 97 | Tie |
| SEQC2 HCC1395 tumour purity, coverage and normal contamination, SNV F1 (Sahraeian et al. 2022 Table S3) | SEQC2 tumour-normal titration: HCC1395 gDNA mixed with HCC1395BL gDNA at 5-100% tumour purity, 10x-300x WGS | F1 (SNVs, tumour SPP_300x_20%T with normal SPP_300x_100%N), percent | 76.8 | 91.2 | NeuSomatic |
| SEQC2 HCC1395 tumour purity, coverage and normal contamination, SNV F1 (Sahraeian et al. 2022 Table S3) | SEQC2 tumour-normal titration: HCC1395 gDNA mixed with HCC1395BL gDNA at 5-100% tumour purity, 10x-300x WGS | F1 (SNVs, tumour SPP_300x_5%T with normal SPP_300x_100%N), percent | 13.2 | 61.9 | NeuSomatic |
| SEQC2 HCC1395 tumour purity, coverage and normal contamination, SNV F1 (Sahraeian et al. 2022 Table S3) | SEQC2 tumour-normal titration: HCC1395 gDNA mixed with HCC1395BL gDNA at 5-100% tumour purity, 10x-300x WGS | F1 (SNVs, tumour SPP_300x_50%T with normal SPP_300x_100%N), percent | 90.2 | 96.6 | NeuSomatic |
| SEQC2 HCC1395 tumour purity, coverage and normal contamination, SNV F1 (Sahraeian et al. 2022 Table S3) | SEQC2 tumour-normal titration: HCC1395 gDNA mixed with HCC1395BL gDNA at 5-100% tumour purity, 10x-300x WGS | F1 (SNVs, tumour SPP_300x_75%T with normal SPP_300x_100%N), percent | 93.8 | 97.5 | NeuSomatic |
| SEQC2 HCC1395 tumour purity, coverage and normal contamination, SNV F1 (Sahraeian et al. 2022 Table S3) | SEQC2 tumour-normal titration: HCC1395 gDNA mixed with HCC1395BL gDNA at 5-100% tumour purity, 10x-300x WGS | F1 (SNVs, tumour SPP_30x_10%T with normal SPP_30x_100%N), percent | 10 | 23.6 | NeuSomatic |
| SEQC2 HCC1395 tumour purity, coverage and normal contamination, SNV F1 (Sahraeian et al. 2022 Table S3) | SEQC2 tumour-normal titration: HCC1395 gDNA mixed with HCC1395BL gDNA at 5-100% tumour purity, 10x-300x WGS | F1 (SNVs, tumour SPP_30x_100%T with normal SPP_30x_100%N), percent | 84.5 | 84 | Tie |
| SEQC2 HCC1395 tumour purity, coverage and normal contamination, SNV F1 (Sahraeian et al. 2022 Table S3) | SEQC2 tumour-normal titration: HCC1395 gDNA mixed with HCC1395BL gDNA at 5-100% tumour purity, 10x-300x WGS | F1 (SNVs, tumour SPP_30x_20%T with normal SPP_30x_100%N), percent | 34.1 | 45.6 | NeuSomatic |
| SEQC2 HCC1395 tumour purity, coverage and normal contamination, SNV F1 (Sahraeian et al. 2022 Table S3) | SEQC2 tumour-normal titration: HCC1395 gDNA mixed with HCC1395BL gDNA at 5-100% tumour purity, 10x-300x WGS | F1 (SNVs, tumour SPP_30x_5%T with normal SPP_30x_100%N), percent | 1.9 | 9.1 | NeuSomatic |
| SEQC2 HCC1395 tumour purity, coverage and normal contamination, SNV F1 (Sahraeian et al. 2022 Table S3) | SEQC2 tumour-normal titration: HCC1395 gDNA mixed with HCC1395BL gDNA at 5-100% tumour purity, 10x-300x WGS | F1 (SNVs, tumour SPP_30x_50%T with normal SPP_30x_100%N), percent | 71.8 | 69.4 | MuSE |
| SEQC2 HCC1395 tumour purity, coverage and normal contamination, SNV F1 (Sahraeian et al. 2022 Table S3) | SEQC2 tumour-normal titration: HCC1395 gDNA mixed with HCC1395BL gDNA at 5-100% tumour purity, 10x-300x WGS | F1 (SNVs, tumour SPP_30x_75%T with normal SPP_30x_100%N), percent | 81.2 | 82.3 | NeuSomatic |
| SEQC2 HCC1395 tumour purity, coverage and normal contamination, SNV F1 (Sahraeian et al. 2022 Table S3) | SEQC2 tumour-normal titration: HCC1395 gDNA mixed with HCC1395BL gDNA at 5-100% tumour purity, 10x-300x WGS | F1 (SNVs, tumour SPP_50x_10%T with normal SPP_50x_100%N), percent | 14.7 | 35.8 | NeuSomatic |
| SEQC2 HCC1395 tumour purity, coverage and normal contamination, SNV F1 (Sahraeian et al. 2022 Table S3) | SEQC2 tumour-normal titration: HCC1395 gDNA mixed with HCC1395BL gDNA at 5-100% tumour purity, 10x-300x WGS | F1 (SNVs, tumour SPP_50x_100%T with normal SPP_50x_100%N), percent | 88.6 | 91.8 | NeuSomatic |
| SEQC2 HCC1395 tumour purity, coverage and normal contamination, SNV F1 (Sahraeian et al. 2022 Table S3) | SEQC2 tumour-normal titration: HCC1395 gDNA mixed with HCC1395BL gDNA at 5-100% tumour purity, 10x-300x WGS | F1 (SNVs, tumour SPP_50x_20%T with normal SPP_50x_100%N), percent | 44.7 | 62.9 | NeuSomatic |
| SEQC2 HCC1395 tumour purity, coverage and normal contamination, SNV F1 (Sahraeian et al. 2022 Table S3) | SEQC2 tumour-normal titration: HCC1395 gDNA mixed with HCC1395BL gDNA at 5-100% tumour purity, 10x-300x WGS | F1 (SNVs, tumour SPP_50x_5%T with normal SPP_50x_100%N), percent | 2.3 | 13.8 | NeuSomatic |
| SEQC2 HCC1395 tumour purity, coverage and normal contamination, SNV F1 (Sahraeian et al. 2022 Table S3) | SEQC2 tumour-normal titration: HCC1395 gDNA mixed with HCC1395BL gDNA at 5-100% tumour purity, 10x-300x WGS | F1 (SNVs, tumour SPP_50x_50%T with normal SPP_50x_100%N), percent | 79.3 | 86.6 | NeuSomatic |
| SEQC2 HCC1395 tumour purity, coverage and normal contamination, SNV F1 (Sahraeian et al. 2022 Table S3) | SEQC2 tumour-normal titration: HCC1395 gDNA mixed with HCC1395BL gDNA at 5-100% tumour purity, 10x-300x WGS | F1 (SNVs, tumour SPP_50x_75%T with normal SPP_50x_100%N), percent | 85.9 | 91 | NeuSomatic |
| SEQC2 HCC1395 tumour purity, coverage and normal contamination, SNV F1 (Sahraeian et al. 2022 Table S3) | SEQC2 tumour-normal titration: HCC1395 gDNA mixed with HCC1395BL gDNA at 5-100% tumour purity, 10x-300x WGS | F1 (SNVs, tumour SPP_80x_10%T with normal SPP_80x_100%N), percent | 20.8 | 56.5 | NeuSomatic |
| SEQC2 HCC1395 tumour purity, coverage and normal contamination, SNV F1 (Sahraeian et al. 2022 Table S3) | SEQC2 tumour-normal titration: HCC1395 gDNA mixed with HCC1395BL gDNA at 5-100% tumour purity, 10x-300x WGS | F1 (SNVs, tumour SPP_80x_10%T with normal SPP_80x_95%N), percent | 2.2 | 32.4 | NeuSomatic |
| SEQC2 HCC1395 tumour purity, coverage and normal contamination, SNV F1 (Sahraeian et al. 2022 Table S3) | SEQC2 tumour-normal titration: HCC1395 gDNA mixed with HCC1395BL gDNA at 5-100% tumour purity, 10x-300x WGS | F1 (SNVs, tumour SPP_80x_100%T with normal SPP_80x_100%N), percent | 91.6 | 95.2 | NeuSomatic |
| SEQC2 HCC1395 tumour purity, coverage and normal contamination, SNV F1 (Sahraeian et al. 2022 Table S3) | SEQC2 tumour-normal titration: HCC1395 gDNA mixed with HCC1395BL gDNA at 5-100% tumour purity, 10x-300x WGS | F1 (SNVs, tumour SPP_80x_100%T with normal SPP_80x_95%N), percent | 59.5 | 91.5 | NeuSomatic |
| SEQC2 HCC1395 tumour purity, coverage and normal contamination, SNV F1 (Sahraeian et al. 2022 Table S3) | SEQC2 tumour-normal titration: HCC1395 gDNA mixed with HCC1395BL gDNA at 5-100% tumour purity, 10x-300x WGS | F1 (SNVs, tumour SPP_80x_20%T with normal SPP_80x_100%N), percent | 55 | 78.9 | NeuSomatic |
| SEQC2 HCC1395 tumour purity, coverage and normal contamination, SNV F1 (Sahraeian et al. 2022 Table S3) | SEQC2 tumour-normal titration: HCC1395 gDNA mixed with HCC1395BL gDNA at 5-100% tumour purity, 10x-300x WGS | F1 (SNVs, tumour SPP_80x_20%T with normal SPP_80x_95%N), percent | 12.2 | 60.2 | NeuSomatic |
| SEQC2 HCC1395 tumour purity, coverage and normal contamination, SNV F1 (Sahraeian et al. 2022 Table S3) | SEQC2 tumour-normal titration: HCC1395 gDNA mixed with HCC1395BL gDNA at 5-100% tumour purity, 10x-300x WGS | F1 (SNVs, tumour SPP_80x_5%T with normal SPP_80x_100%N), percent | 3.3 | 27.5 | NeuSomatic |
| SEQC2 HCC1395 tumour purity, coverage and normal contamination, SNV F1 (Sahraeian et al. 2022 Table S3) | SEQC2 tumour-normal titration: HCC1395 gDNA mixed with HCC1395BL gDNA at 5-100% tumour purity, 10x-300x WGS | F1 (SNVs, tumour SPP_80x_50%T with normal SPP_80x_100%N), percent | 83.9 | 91.7 | NeuSomatic |
| SEQC2 HCC1395 tumour purity, coverage and normal contamination, SNV F1 (Sahraeian et al. 2022 Table S3) | SEQC2 tumour-normal titration: HCC1395 gDNA mixed with HCC1395BL gDNA at 5-100% tumour purity, 10x-300x WGS | F1 (SNVs, tumour SPP_80x_50%T with normal SPP_80x_95%N), percent | 39.8 | 85.7 | NeuSomatic |
| SEQC2 HCC1395 tumour purity, coverage and normal contamination, SNV F1 (Sahraeian et al. 2022 Table S3) | SEQC2 tumour-normal titration: HCC1395 gDNA mixed with HCC1395BL gDNA at 5-100% tumour purity, 10x-300x WGS | F1 (SNVs, tumour SPP_80x_75%T with normal SPP_80x_100%N), percent | 88.9 | 93.8 | NeuSomatic |
| SEQC2 HCC1395 tumour purity, coverage and normal contamination, SNV F1 (Sahraeian et al. 2022 Table S3) | SEQC2 tumour-normal titration: HCC1395 gDNA mixed with HCC1395BL gDNA at 5-100% tumour purity, 10x-300x WGS | F1 (SNVs, tumour SPP_80x_75%T with normal SPP_80x_95%N), percent | 52.3 | 89.2 | NeuSomatic |
| SEQC2 HCC1395 sequencing centre and platform, SNV F1 (Sahraeian et al. 2022 Table S2) | SEQC2 HCC1395/HCC1395BL WGS replicate pairs from multiple sequencing centres | F1 (SNVs, average over the 21 replicate pairs as printed), percent | 88.1 | 91.8 | NeuSomatic |
| SEQC2 HCC1395 sequencing centre and platform, SNV F1 (Sahraeian et al. 2022 Table S2) | SEQC2 HCC1395/HCC1395BL WGS replicate pairs from multiple sequencing centres | F1 (SNVs, tumour WGS_EA_T_1 with normal WGS_EA_N_1), percent | 90.2 | 93.8 | NeuSomatic |
| SEQC2 HCC1395 sequencing centre and platform, SNV F1 (Sahraeian et al. 2022 Table S2) | SEQC2 HCC1395/HCC1395BL WGS replicate pairs from multiple sequencing centres | F1 (SNVs, tumour WGS_FD_T_1 with normal WGS_FD_N_1), percent | 88 | 91.8 | NeuSomatic |
| SEQC2 HCC1395 sequencing centre and platform, SNV F1 (Sahraeian et al. 2022 Table S2) | SEQC2 HCC1395/HCC1395BL WGS replicate pairs from multiple sequencing centres | F1 (SNVs, tumour WGS_FD_T_2 with normal WGS_FD_N_2), percent | 88.6 | 91.8 | NeuSomatic |
| SEQC2 HCC1395 sequencing centre and platform, SNV F1 (Sahraeian et al. 2022 Table S2) | SEQC2 HCC1395/HCC1395BL WGS replicate pairs from multiple sequencing centres | F1 (SNVs, tumour WGS_FD_T_3 with normal WGS_FD_N_3), percent | 88.4 | 91.8 | NeuSomatic |
| SEQC2 HCC1395 sequencing centre and platform, SNV F1 (Sahraeian et al. 2022 Table S2) | SEQC2 HCC1395/HCC1395BL WGS replicate pairs from multiple sequencing centres | F1 (SNVs, tumour WGS_IL_T_1 with normal WGS_IL_N_1), percent | 90.6 | 95 | NeuSomatic |
| SEQC2 HCC1395 sequencing centre and platform, SNV F1 (Sahraeian et al. 2022 Table S2) | SEQC2 HCC1395/HCC1395BL WGS replicate pairs from multiple sequencing centres | F1 (SNVs, tumour WGS_IL_T_2 with normal WGS_IL_N_2), percent | 89 | 93.3 | NeuSomatic |
| SEQC2 HCC1395 sequencing centre and platform, SNV F1 (Sahraeian et al. 2022 Table S2) | SEQC2 HCC1395/HCC1395BL WGS replicate pairs from multiple sequencing centres | F1 (SNVs, tumour WGS_IL_T_3 with normal WGS_IL_N_3), percent | 88.7 | 93.4 | NeuSomatic |
| SEQC2 HCC1395 sequencing centre and platform, SNV F1 (Sahraeian et al. 2022 Table S2) | SEQC2 HCC1395/HCC1395BL WGS replicate pairs from multiple sequencing centres | F1 (SNVs, tumour WGS_LL_T_1 with normal WGS_LL_N_1), percent | 80.6 | 79.7 | MuSE |
| SEQC2 HCC1395 sequencing centre and platform, SNV F1 (Sahraeian et al. 2022 Table S2) | SEQC2 HCC1395/HCC1395BL WGS replicate pairs from multiple sequencing centres | F1 (SNVs, tumour WGS_NC_T_1 with normal WGS_NC_N_1), percent | 88 | 91.5 | NeuSomatic |
| SEQC2 HCC1395 sequencing centre and platform, SNV F1 (Sahraeian et al. 2022 Table S2) | SEQC2 HCC1395/HCC1395BL WGS replicate pairs from multiple sequencing centres | F1 (SNVs, tumour WGS_NS_T_1 with normal WGS_NS_N_1), percent | 88.4 | 91.7 | NeuSomatic |
| SEQC2 HCC1395 sequencing centre and platform, SNV F1 (Sahraeian et al. 2022 Table S2) | SEQC2 HCC1395/HCC1395BL WGS replicate pairs from multiple sequencing centres | F1 (SNVs, tumour WGS_NS_T_2 with normal WGS_NS_N_2), percent | 85.9 | 90.6 | NeuSomatic |
| SEQC2 HCC1395 sequencing centre and platform, SNV F1 (Sahraeian et al. 2022 Table S2) | SEQC2 HCC1395/HCC1395BL WGS replicate pairs from multiple sequencing centres | F1 (SNVs, tumour WGS_NS_T_3 with normal WGS_NS_N_3), percent | 87.6 | 90.8 | NeuSomatic |
| SEQC2 HCC1395 sequencing centre and platform, SNV F1 (Sahraeian et al. 2022 Table S2) | SEQC2 HCC1395/HCC1395BL WGS replicate pairs from multiple sequencing centres | F1 (SNVs, tumour WGS_NS_T_4 with normal WGS_NS_N_4), percent | 87.6 | 90.8 | NeuSomatic |
| SEQC2 HCC1395 sequencing centre and platform, SNV F1 (Sahraeian et al. 2022 Table S2) | SEQC2 HCC1395/HCC1395BL WGS replicate pairs from multiple sequencing centres | F1 (SNVs, tumour WGS_NS_T_5 with normal WGS_NS_N_5), percent | 84.8 | 90.5 | NeuSomatic |
| SEQC2 HCC1395 sequencing centre and platform, SNV F1 (Sahraeian et al. 2022 Table S2) | SEQC2 HCC1395/HCC1395BL WGS replicate pairs from multiple sequencing centres | F1 (SNVs, tumour WGS_NS_T_6 with normal WGS_NS_N_6), percent | 88.4 | 92.4 | NeuSomatic |
| SEQC2 HCC1395 sequencing centre and platform, SNV F1 (Sahraeian et al. 2022 Table S2) | SEQC2 HCC1395/HCC1395BL WGS replicate pairs from multiple sequencing centres | F1 (SNVs, tumour WGS_NS_T_7 with normal WGS_NS_N_7), percent | 84.9 | 89.8 | NeuSomatic |
| SEQC2 HCC1395 sequencing centre and platform, SNV F1 (Sahraeian et al. 2022 Table S2) | SEQC2 HCC1395/HCC1395BL WGS replicate pairs from multiple sequencing centres | F1 (SNVs, tumour WGS_NS_T_8 with normal WGS_NS_N_8), percent | 86.2 | 90.7 | NeuSomatic |
| SEQC2 HCC1395 sequencing centre and platform, SNV F1 (Sahraeian et al. 2022 Table S2) | SEQC2 HCC1395/HCC1395BL WGS replicate pairs from multiple sequencing centres | F1 (SNVs, tumour WGS_NS_T_9 with normal WGS_NS_N_9), percent | 87.2 | 91.2 | NeuSomatic |
| SEQC2 HCC1395 sequencing centre and platform, SNV F1 (Sahraeian et al. 2022 Table S2) | SEQC2 HCC1395/HCC1395BL WGS replicate pairs from multiple sequencing centres | F1 (SNVs, tumour WGS_NV_T_1 with normal WGS_NV_N_1), percent | 92.2 | 95.7 | NeuSomatic |
| SEQC2 HCC1395 sequencing centre and platform, SNV F1 (Sahraeian et al. 2022 Table S2) | SEQC2 HCC1395/HCC1395BL WGS replicate pairs from multiple sequencing centres | F1 (SNVs, tumour WGS_NV_T_2 with normal WGS_NV_N_2), percent | 92.3 | 95.7 | NeuSomatic |
| SEQC2 HCC1395 sequencing centre and platform, SNV F1 (Sahraeian et al. 2022 Table S2) | SEQC2 HCC1395/HCC1395BL WGS replicate pairs from multiple sequencing centres | F1 (SNVs, tumour WGS_NV_T_3 with normal WGS_NV_N_3), percent | 92.2 | 95.9 | NeuSomatic |